157 related articles for article (PubMed ID: 20361466)
1. Monoclonal antibodies in advanced B-cell lymphomas.
Ujjani C; Cheson BD
Oncology (Williston Park); 2010 Feb; 24(2):156-66. PubMed ID: 20361466
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for the treatment of diffuse large B-cell lymphomas.
Held G; Pöschel V; Pfreundschuh M
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1175-86. PubMed ID: 16925484
[TBL] [Abstract][Full Text] [Related]
3. Monoclonal antibody therapy for B-cell malignancies.
Cheson BD
Semin Oncol; 2006 Apr; 33(2 Suppl 5):S2-14. PubMed ID: 16720198
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic advances for indolent lymphomas].
Ogura M
Nihon Rinsho; 2000 Mar; 58(3):682-94. PubMed ID: 10741147
[TBL] [Abstract][Full Text] [Related]
5. Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.
Hernandez-Ilizaliturri FJ; Gowda A; Czuczman MS
Clin Adv Hematol Oncol; 2004 Sep; 2(9):606-18. PubMed ID: 16163245
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
7. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
8. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
9. Rituximab and other emerging antibodies as molecular target-based therapy of lymphoma.
Tobinai K
Int J Clin Oncol; 2003 Aug; 8(4):212-23. PubMed ID: 12955576
[TBL] [Abstract][Full Text] [Related]
10. Clinical status and optimal use of rituximab for B-cell lymphomas.
McLaughlin P; White CA; Grillo-López AJ; Maloney DG
Oncology (Williston Park); 1998 Dec; 12(12):1763-9; discussion 1769-70, 1775-7,. PubMed ID: 9874849
[TBL] [Abstract][Full Text] [Related]
11. Emerging treatments for indolent lymphoma.
Cheson BD; Gregory SA; Marcus R
Clin Adv Hematol Oncol; 2007 May; 5(5 Suppl 8):1-9; quiz 11-2. PubMed ID: 17637594
[TBL] [Abstract][Full Text] [Related]
12. [Rituximab].
Okamoto R; Maeda Y; Sasaki T
Gan To Kagaku Ryoho; 2003 Aug; 30(8):1085-93. PubMed ID: 12938262
[TBL] [Abstract][Full Text] [Related]
13. Indolent lymphomas: current and emerging treatment approaches.
Maloney D; Kahl BS; Dreyling M
Clin Adv Hematol Oncol; 2006 Sep; 4(9 Suppl 20):1-10; quiz 11-2. PubMed ID: 17139243
[TBL] [Abstract][Full Text] [Related]
14. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
15. Maintenance therapy for low-grade lymphomas: has the time come?
Cartron G; Solal-Céligny P
Curr Opin Oncol; 2007 Sep; 19(5):425-32. PubMed ID: 17762565
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibodies for the treatment of hematologic malignancies: clinical trials in Japan.
Tobinai K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S90-6. PubMed ID: 12819934
[TBL] [Abstract][Full Text] [Related]
17. The expanding role of rituximab and radioimmunotherapy in the treatment of B-cell lymphomas.
Jacobs SA; Foon KA
Expert Opin Biol Ther; 2007 Nov; 7(11):1749-62. PubMed ID: 17961097
[TBL] [Abstract][Full Text] [Related]
18. Monoclonal antibody as therapy for malignant lymphomas.
Coiffier B
C R Biol; 2006 Apr; 329(4):241-54. PubMed ID: 16644494
[TBL] [Abstract][Full Text] [Related]
19. Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.
Hohloch K; Sahlmann CO; Lakhani VJ; Wulf G; Glass B; Hasenkamp J; Meller J; Riggert J; Trümper L; Griesinger F
Ann Hematol; 2011 Nov; 90(11):1307-15. PubMed ID: 21360108
[TBL] [Abstract][Full Text] [Related]
20. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
